Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Closes First Part of Financing Round

NEW YORK (GenomeWeb) – Protagen said today that it has closed the first part of a financing round that targets €10 million ($12.5 million).

The German firm did not disclose the amount raised in the first close. It added that it plans a second closing in the third quarter of 2015 with additional new investors.

Qiagen participated in the first close, joining existing investors MIG Fonds, NRW.Bank, and Protagen management. Qiagen and Protagen last month announced a long-term collaboration on research into protein-based companion diagnostics for autoimmune disorders. 

Protagen CEO Stefan Müllner said in a statement that it will use the funds to complete and commercialize in vitro diagnostic tests for rheumatoid arthritis, systemic lupus, and systemic sclerosis.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.